Anika Therapeutics, Inc. — FY2015 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2015. The filing is an annual report, not a quarterly filing; fourth-quarter 2015 data are included in the unaudited quarterly financial information.
Business context
Anika is a global orthopedic medicines company focused on hyaluronic-acid-based products for osteoarthritis, regenerative medicine, wound care, surgical adhesion prevention, ophthalmic surgery, and veterinary applications. Orthobiologics represented 84% of 2015 product revenue. The company primarily sells through distributors and strategic partners, with Mitek accounting for 72% of product revenue.
Key marketed products include ORTHOVISC and MONOVISC. CINGAL received Health Canada approval in November 2015, while U.S. and European approvals remained pending. Anika also advanced HYALOFAST clinical development and received CE Mark approval for HYALOSPINE.
Financial performance and liquidity
| Metric | 2015 | 2014 | Change |
|---|---|---|---|
| Product revenue | $87.7 million | $75.5 million | +16% |
| Licensing, milestone and contract revenue | $5.3 million | $30.1 million | -82% |
| Total revenue | $93.0 million | $105.6 million | -12% |
| Product gross profit | $66.6 million | $54.5 million | +22% |
| Product gross margin | 76% | 72% | +4 percentage points |
| Income from operations | $48.1 million | $61.4 million | -22% |
| Net income | $30.8 million | $38.3 million | -20% |
| Diluted EPS | $2.01 | $2.51 | -20% |
| Cash provided by operating activities | $39.1 million | $40.0 million | -2% |
Product revenue growth was led by orthobiologics, which increased 18% to $73.2 million, and dermal products, which increased 70% to $2.3 million. Surgical revenue declined 1% to $5.8 million. Other product revenue was $6.4 million.
The decline in total revenue and earnings primarily reflected the absence of approximately $29.7 million of MONOVISC-related milestone and contract revenue recognized in 2014. In 2015, Anika recognized a $5.0 million MONOVISC milestone after U.S. annual end-user sales exceeded $50 million. Product gross margin improved because of manufacturing efficiencies and a more favorable product mix.
Research and development expense increased 10% to $9.0 million. Selling, general and administrative expense declined 2% to $14.8 million. The effective tax rate was 36.3%, compared with 37.7% in 2014. Net margin was approximately 33% of total revenue.
Cash, cash equivalents and investments totaled $138.5 million at year-end, including $110.7 million of cash and cash equivalents and $27.8 million of investments. Working capital was $159.2 million. The company reported no long-term debt and stated that available resources were adequate to support operations for at least the next twelve months.
Material changes versus the prior comparable period
- Product revenue increased $12.2 million, or 16%, despite lower revenue from Mitek during its planned inventory reduction period.
- Total revenue decreased $12.6 million because 2014 included substantial MONOVISC approval, launch, reimbursement-code, and related milestone revenue.
- Product gross margin expanded from 72% to 76%.
- Operating cash flow remained strong but decreased slightly as lower net income and higher accounts receivable and inventory requirements offset higher accounts payable.
- Capital spending increased materially. Anika spent approximately $9 million on expanding its Bedford, Massachusetts manufacturing capabilities, compared with $1.6 million of property and equipment purchases in 2014.
- Anika recorded a $0.7 million impairment charge for acquired in-process research and development after discontinuing development of a Hemostatic Patch project.
- The company adopted ASU 2015-17 for deferred-tax presentation retrospectively; the adoption did not affect earnings, retained earnings, or cash flows.
Guidance, outlook, commentary and risks
- Management expected orthobiologics revenue to increase in 2016, supported by MONOVISC growth and planned CINGAL launches in Canada and Europe.
- CINGAL commercial introduction in Canada was expected in the second quarter of 2016, and CE Mark approval was expected by the end of April 2016. The FDA had assigned CINGAL to CDER, and preliminary indications suggested that additional clinical work might be required for U.S. approval.
- Management expected research and development spending and selling, general and administrative expense to increase in 2016.
- Surgical revenue was expected to decline moderately, while other product revenue was expected to decrease, primarily because of foreign exchange and anticipated lower veterinary revenue.
- Anika expected to spend approximately $15 million over the following 12 to 18 months to transfer HYAFF manufacturing from an Italian contract manufacturer to Bedford. The transfer could create supply interruption, validation, regulatory, and execution risks.
- Anika planned to move its Italian subsidiary to a new Padova facility in late 2016. Construction or permitting delays could disrupt operations.
- Revenue concentration is significant: five customers represented 84% of product revenue, Mitek represented 72%, and Mitek represented 60% of accounts receivable at year-end.
- Major risks include regulatory delays or denials, additional clinical requirements for CINGAL, competition and pricing pressure, reimbursement changes, dependence on distributors, manufacturing and raw-material disruptions, foreign currency exposure, intellectual-property disputes, product liability, and possible impairment of long-lived assets.
- The Genzyme patent litigation concerning MONOVISC was dismissed with prejudice in March 2014. Other ordinary-course legal proceedings were not expected to materially affect financial position, results of operations, or cash flow.
- After year-end, Anika entered into a $25 million accelerated share repurchase agreement in February 2016 and initially received 377,155 shares. Final settlement was expected in the third quarter of 2016.
Important facts for investors to verify
- Whether CINGAL obtained European and U.S. regulatory approvals and the amount and timing of any additional clinical expenditures.
- Actual 2016 CINGAL launches, direct-sales execution, reimbursement coverage, and commercial traction.
- Progress, total cost, validation, and supply continuity related to the HYAFF manufacturing transfer.
- Continued purchasing levels and contract terms with Mitek, given its 72% share of 2015 product revenue.
- Whether product revenue growth can offset the expected decline in licensing and milestone revenue after the 2015 MONOVISC milestone.
- Cash usage, capital expenditures, and liquidity after the $25 million share repurchase and planned manufacturing investments.
- Potential additional impairment charges, inventory write-downs, regulatory contingencies, and foreign-exchange effects.